Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Jakob Storebø, Ole; Pedersen, Nadia; Ramstad, E; Laerke Kielsholm, Maja; Sofie Nielsen, Signe; B. Krogh, Helle; Renato Moreira Maia, Carlos; L Magnusson, Frederik; Holmskov, Mathilde; Gerner, Trine; Skoog, Maria; Rosendal, Susanne; Groth, Camilla; Gillies, Donna; Rasmussen, Kirsten; Gauci, Dorothy; Zwi, Morris; Kirubakaran, Richard; Jul Håkonsen, Sasja; Aagaard, Lise; Simonsen, Erik; Gluud, Christian

doi:10.1002/14651858.cd012069.pub2

Public

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Published in Cochrane Database of Systematic Reviews • May 10, 2018

Authors:

Ole Jakob Storebø

Nadia Pedersen

E Ramstad

Abstract

BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable eff...

Subject

Methylphenidate

Attention deficit hyperactivity disorder

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!